



## Press Release

### **Hikma Collaborates with the Department of Leukemia at the MD Anderson Cancer Center to Host the Annual Middle East Forum**

*Addressing the treatment of leukemia and other blood cancers*

Amman, April 2017 – Under its ongoing efforts to advance scientific awareness within the medical community, [Hikma Pharmaceuticals](#), the fast growing multinational pharmaceutical group, has hosted the first annual ‘Hikma Cancer Network – Middle East Forum of Hematologic Malignancies’, in collaboration with the University of Texas MD Anderson Cancer Center, the Department of Leukemia. The educational and networking event took place on 20 and 21 April, 2017, at the King Hussein Bin Talal Convention Centre at the Dead Sea area in Jordan.

The Forum marked the first event to be held under the Group’s recently established collaboration with the Department of Leukemia at the University of Texas MD Anderson Cancer Center, a world-renowned center dedicated to quality patient care, innovative research and the development of more effective treatments for all types of leukemia.

The two-day educational forum, which aimed to provide blood cancer specialists with cutting-edge knowledge in their fields, gathered physicians from across the Middle East and North Africa (MENA), drawing an audience of more than 100 medical doctors from Jordan, Lebanon, Syria, Iraq, Palestine, Saudi Arabia, Kuwait, UAE, Egypt, Sudan and Tunisia.

Throughout the Forum, distinguished speakers and experts from the Department of Leukemia at the MD Anderson Cancer Center, as well as representatives from other leading institutions, gave presentations on the state-of-the-art treatments utilized in the management of blood cancers. During a ‘Meet the Experts’ session, participants actively engaged in discussions regarding best practices and the challenges faced in the routine clinical setting.

“I am pleased to announce this positive collaboration with the University of Texas MD Anderson Cancer Center’s esteemed Department of Leukemia,” said Mazen Darwazah, **Hikma** Executive Vice Chairman, President and CEO of MENA and Emerging Markets.

“This collaboration not only re-enforces our commitment to continuous medical education, but also enables us to fulfill our obligation to the communities in which we operate by allowing us to meet the needs of our patients and help create sustainable healthcare.”

In turn, Dr. Hagop Kantarjian, Chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, said, “We are very pleased to collaborate with **Hikma** and to co-organize these annual educational meetings, which provide us with an opportunity to share the latest and most advanced developments in cancer medicine with physicians in the MENA region.”

**-End-**

**About Hikma Pharmaceuticals**

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: “Branded”, “Injectables” and “Generics”, based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. Hikma currently employs over 8,500 staff members worldwide.

For further information and latest news updates, visit [www.Hikma.com](http://www.Hikma.com) or contact:

Hana Darwazeh Ramadan

Email: [Media@Hikma.com](mailto:Media@Hikma.com)

Tel: +962 6 580 2900

**About the Department of Leukemia, the University of Texas MD Anderson Cancer Center** please visit

<https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/leukemia.html>